CTNM · Contineum Therapeutics Inc
United States · RS rating 17 · As of 2026-11-03
| Price | 9.69 USD |
|---|---|
| 1-day change | +1.4% |
| RS rating (overall / 1M / 3M / 12M) | 17 / 18 / 16 / 42 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 25 / 12 / 25 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -8.9% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +44.9% |
| Market cap (USD) | $463.7M |